Related Experiment Video
Updated: May 16, 2026
07:32
Standardized Histomorphometric Evaluation of Osteoarthritis in a Surgical Mouse Model
Published on: May 6, 2020
Prognostic biomarkers in osteoarthritis
Mukundan Attur1, Svetlana Krasnokutsky-Samuels, Jonathan Samuels
1New York University School of Medicine, and Hospital for Joint Diseases at NYU Langone Medical Center, New York, New York 10003, USA.
Current Opinion in Rheumatology
|November 22, 2012
Summary
New biomarkers can identify osteoarthritis patients at risk for disease progression. Combining biochemical and imaging markers may predict early onset and disease burden, aiding in the development of new treatments.
Area of Science:
- Biomarkers and Molecular Diagnostics
- Orthopedics and Musculoskeletal Diseases
Background:
- Radiography is insensitive to early molecular changes in osteoarthritis (OA), necessitating better methods for risk identification.
- Accurate identification of patients at risk for OA progression is crucial for effective management and treatment development.
Purpose of the Study:
- To review recent advancements in biochemical and imaging biomarkers for identifying OA patients at risk of disease progression.
- To highlight the potential of these biomarkers in understanding OA pathogenesis and developing targeted therapies.
Main Methods:
- Evaluation of biochemical markers including anabolic, catabolic, and inflammatory molecules.
- Assessment of promising cartilage and bone degradation/synthesis biomarkers.
- Integration of biochemical markers with imaging biomarkers for predictive analysis.
Main Results:
- Several biochemical markers across diverse pathways are under evaluation.
- Promising biomarkers for cartilage and bone changes require further validation in larger cohorts.
- Elevated inflammatory biomarkers are observed in both local and systemic samples.
Conclusions:
- Prognostic biomarkers can stratify knee OA patients based on disease progression rates.
- Biomarker-driven phenotyping can enhance understanding of OA pathogenesis.
- Development of disease-modifying osteoarthritis drugs (DMOADs) may be facilitated by these advancements.
